Friday, 17 Nov 2017

You are here

Long-Term Additive Cardiovascular Benefit of Plaquenil and Aspirin in Lupus

Systemic lupus erythematosus (SLE) is associated with an increased risk of cardiovascular disease (CVD). The cardioprotective benefits of aspirin (ASA) are well known and the ancillary CV and diabetogenic effects of hydroxychloroquine (HCQ) have also been shown.  A current study in the Journal of Rheumatology has shown that thromboprophylaxis with low-dose ASA and HCQ) yields CVD benefits in SLE.

 

They enrolled 189 patients with SLE and monitored them for a median of 13 years and found 10  CVE occurred during followup.  They found that a higher CVE-free rate ASA-treated patients administered a cumulative dose of HCQ > 600 grams, compared with patients receiving ASA alone, or with a cHCQ dose < 600 g (p = 0.04).

Multivariate analysis showed that antimalarials plus ASA protected against thrombosis (HR 0.041 and HR 0.047, respectively), while antiphospholipid antibodies (HR 17.965) and hypertension (HR 18.054) increased the risk of a first CVE.

These data suggest that prolonged use of HCQ plus ASA has a thromboprotective in SLE.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Health Economics of SLE

A number of presentations over the past few days have addressed the health economics of SLE.

Two Lupus Studies

In this session we were given new data on ustekinumab for SLE (abstract 6L). Ustekinumab is an IL12/23 agent already approved for use in psoriasis, psoriatic arthritis and Cohn’s disease.

EULAR/ACR SLE Classification Criteria Update

Today the draft of the new EULAR/ACR lupus classification criteria was presented at the ACR 2017.

Tocilizumab Benefits Persist in SSc

Clinically meaningful improvements in systemic sclerosis among patients treated with subcutaneous tocilizumab (Actemra) persisted during the open-label phase of a multinational randomized phase II trial, researchers reported.

New EULAR/ACR Classification Criteria for Adult and Juvenile Myositis

The European League Against Rheumatism and the American College of Rheumatology (EULAR/ACR) have developed classification criteria for idiopathic inflammatory myopathies (IIM) based on data from 976 IIM patients (74% adults; 26% children) and 624 non-IIM patients with mimicking conditions (82% adults; 18% children) from 47 rheumatology, dermatology, neurology and paediatric clinics worldwide.